Literature DB >> 28835482

APOL1 and Cardiovascular Disease: A Story in Evolution.

Archna Bajaj1, Katalin Susztak1, Scott M Damrauer2.   

Abstract

Entities:  

Keywords:  Editorials; apolipoproteins; cardiovascular diseases; kidney failure, chronic; prevalence; risk factors

Mesh：

Substances：

Year:  2017        PMID： 28835482      PMCID： PMC5657568          DOI： 10.1161/ATVBAHA.117.309756

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  23 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

2.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease.

Authors:  John Michael Gaziano; John Concato; Mary Brophy; Louis Fiore; Saiju Pyarajan; James Breeling; Stacey Whitbourne; Jennifer Deen; Colleen Shannon; Donald Humphries; Peter Guarino; Mihaela Aslan; Daniel Anderson; Rene LaFleur; Timothy Hammond; Kendra Schaa; Jennifer Moser; Grant Huang; Sumitra Muralidhar; Ronald Przygodzki; Timothy J O'Leary
Journal:  J Clin Epidemiol       Date:  2015-10-09       Impact factor: 6.437

3.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

4.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

5.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

6.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

7.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

8.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension.

Authors:  W McClellan; E Tuttle; A Issa
Journal:  Am J Kidney Dis       Date:  1988-10       Impact factor: 8.860

9.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

10.  Incidence and predictors of end stage renal disease among low-income blacks and whites.

Authors:  Loren Lipworth; Michael T Mumma; Kerri L Cavanaugh; Todd L Edwards; T Alp Ikizler; Robert E Tarone; Joseph K McLaughlin; William J Blot
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240
View more
  4 in total

1.  Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.

Authors:  Ya-Wen Yang; Bibek Poudel; Julia Frederick; Poonam Dhillon; Rojesh Shrestha; Ziyuan Ma; Junnan Wu; Koji Okamoto; Jeffrey B Kopp; Sheri L Booten; Danielle Gattis; Andrew T Watt; Matthew Palmer; Mariam Aghajan; Katalin Susztak
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

2.  APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis.

Authors:  Junnan Wu; Ziyuan Ma; Archana Raman; Pazit Beckerman; Poonam Dhillon; Dhanunjay Mukhi; Matthew Palmer; Hua Chang Chen; Cassiane Robinson Cohen; Thomas Dunn; John Reilly; Nuala Meyer; Michael Shashaty; Zoltan Arany; György Haskó; Krzysztof Laudanski; Adriana Hung; Katalin Susztak
Journal:  Immunity       Date:  2021-10-12       Impact factor: 43.474

3.  Assessing known chronic kidney disease associated genetic variants in Saudi Arabian populations.

Authors:  Cyril Cyrus; Samir Al-Mueilo; Chittibabu Vatte; Shahanas Chathoth; Yun R Li; Hatem Qutub; Rudaynah Al Ali; Fahad Al-Muhanna; Matthew B Lanktree; Khaled Riyad Alkharsah; Abdullah Al-Rubaish; Brian Kim-Mozeleski; Brendan Keating; Amein Al Ali
Journal:  BMC Nephrol       Date:  2018-04-17       Impact factor: 2.388

4.  Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects.

Authors:  Graziella E Ronsein; Tomas Vaisar; W Sean Davidson; Karin E Bornfeldt; Jeffrey L Probstfield; Kevin D O'Brien; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-06-17       Impact factor: 10.514
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.